Respiratory FailureNCT03832387
Non-invasive Ventilation vs Oxygen Therapy After Extubation Failure
A study testing Non-invasive mechanical ventilation, Continuous positive airway pressure and Venturi mask in people with Respiratory Failure, run by Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana at 1 site in Spain.
Trial summary
Non-invasive mechanical ventilation (NIV) has not exhibited a reduction of reintubation after extubation failure compared to oxygen therapy. The reduction of reintubation with NIV versus oxygen therapy in patients with extubation failure was evaluated. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Respiratory Failure
- What is being tested?
- Non-invasive mechanical ventilation, Continuous positive airway pressure and Venturi mask
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 77 participants
- Where
- 1 siteSpain
- Study dates
- 29 Mar 2009to 4 Sep 2016
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Medical and surgical ICU patients with 18 years of age or older
- First episode of mechanical ventilation for more than 24 hours
Who cannot join
- Structural neurological disorder
- Acute toxic-metabolic neurological encephalopathy with neurological deficit [estimated by a Glasgow Coma Score (GCS) <14 points] at the time of weaning
- Neuromuscular disease
- Chronic obstructive pulmonary disease (COPD) receiving NIV
- Limitation of life support therapy during their admission
- Tracheostomized patients
Show all 11Show fewer
- Spinal cord injuries
- Scheduled surgical procedure during the 48 hours following extubation
- Intensive care unit readmission
- Transfer to another centre
- Contraindication to non-invasive mechanical ventilation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Non-Invasive Mechanical Ventilation Versus Oxygen Therapy in Patients With Acute Respiratory Failure After Extubation in a Intensive Care Unit
Non-invasive mechanical ventilation (NIV) has not exhibited a reduction of reintubation after extubation failure compared to oxygen therapy. The reduction of reintubation with NIV versus oxygen therapy in patients with extubation failure was evaluated.
A clinical trial was conducted that included patients who underwent mechanical ventilation and developed acute respiratory failure after extubation. After extubation failure, thirty-three were assigned to NIV and thirty-two were assigned to oxygen therapy.
Read the detailed description
Patients. Medical and surgical patients admitted to intensive care unit with 18 years of age or older in weaning from their first episode of mechanical ventilation for more than 24 hours were included. Patients with structural neurological disorder, acute toxic-metabolic neurological encephalopathy with neurological deficit [estimated by a Glasgow Coma Score <14 points] at the time of weaning, neuromuscular disease, chronic obstructive pulmonary disease receiving non-invasive ventilation, limitation of life support therapy during their admission, tracheostomized patients, spinal cord injuries, scheduled surgical procedure during the 48 hours following extubation, intensive care unit readmission, transfer to another centre or a contraindication to non-invasive ventilation were excluded.
Weaning protocol. The beginning of weaning was considered when patients were conscious, without pain, connected to mechanical ventilation in pressure support ventilation mode, fraction of inspired oxygen ≤0.5, positive end-expiratory pressure +5cmH20, dopamine ≤5 mcgr/kg/min or noradrenaline ≤0.2 mcgr/kg/min, temperature <38ºC and absence of metabolic acidosis. Weaning consisted of a spontaneous breathing trial, which is routinely performed in our unit with a T-tube connected to an oxygen source . The following conditions indicated a successful spontaneous breathing trial: oxygen partial pressure ≥60 mmHg or transcutaneous oxygen saturation>90% with fraction of inspired oxygen <0.5, carbon dioxide partial pressure <50 mmHg (or an increase <8 mmHg), pH >7.32, respiratory rate <35 bpm (or an increase <50%), heart rate <140 bpm (or an increase <20%), systolic blood pressure <180 mmHg, and absence of cardiac arrhythmias after a minimum period of 30-120 min. Once the test was completed, extubation and subsequent placement of a Venturi oxygen mask with 0.3-0.4 fraction of inspired oxygen was performed. The physician in charge was responsible for the process of removal of mechanical ventilation and subsequent extubation. In the case of T-tube test failure, the patient was reconnected to the ventilator. Patient who presented clinical deterioration within 48 hours after extubation (work of breathing, use of accessory muscles, paradoxical breathing) and/or respiratory-gasometric deterioration [respiratory rate >25 bpm or increase of >50% with respect to the baseline respiratory rate, oxygen partial pressure <65 mmHg, carbon dioxide partial pressure >45 mmHg or pH <7.33) [19] and who were candidates for non-invasive ventilation were included in the study. Extubation failure was classified as follows: 1) Acute respiratory failure secondary to airway problems: obstruction of the upper airway and aspiration or excess of secretions; 2) Acute respiratory failure not dependent of the airway: acute pulmonary oedema, congestive heart failure, hypoxemic and/or hypercapnic acute respiratory failure, encephalopathy and others (digestive bleeding, shock, etc.). Patients who required immediate reintubation after extubation failure were not included.
After confirming extubation failure and the possibility of eligibility to participate in the study, the patient was assigned to a group (non-invasive ventilation group or oxygen group) through the opening of a sealed envelope. Previously, a simple randomisation by a computerised system had been performed by a physician not involved in the study.
Non-invasive ventilation. BiPAP Vision and continuous positive airway pressure devices were used. For the BiPAP Vision, oronasal and facial masks and an active humidification system were used. Procedure: Once the patient was informed of the procedure, the type of mask was selected according to the clinical situation and anatomy of the patient, and the harness was placed. Ventilation was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. The rise time was 0.1-0.2 seconds. Continuous positive airway pressure. A continuous positive airway pressure device was used through the oronasal mask on the patient. The minimum initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O. The objective pressures of both devices were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. The fraction of inspired oxygen was increased in both devices until a transcutaneous oxygen saturation of 94-96% was achieved. Once the patient's cooperation and sufficient adaptability were achieved, the mask was adjusted to the harness with adjustable straps.
Oxygen therapy. The control group received oxygen therapy using a Venturi mask with an fraction of inspired oxygen up to 0.5 or using a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2 (estimated fraction of inspired oxygen of 1.0).
Both non-invasive ventilation/continuous positive airway pressure and oxygen therapy were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective. Withdrawal of non-invasive ventilation/continuous positive airway pressure was performed progressively with reduction of inspiratory airway pressure/expiratory positive airway pressure or positive end-expiratory pressure levels until complete disconnection of non-invasive ventilation. In both groups (study and control), after improvement, the fraction of inspired oxygen of the Venturi mask was set to 0.3-0.4. The criteria for failure of both non-invasive ventilation and oxygen therapy were: absence of clinical improvement (respiratory rate>35 bpm, use of accessory muscles, thoracoabdominal asynchrony, encephalopathy) or deterioration of oxygenation (decrease in oxygen partial pressure or in oxygen partial pressure to fraction of inspired oxygen ratio), haemodynamic (noradrenaline >0.5 mcgr/kg/min) or ventilation (increase in carbon dioxide partial pressure and decrease in pH) parameters. Modifications of fraction of inspired oxygen and inspiratory positive airway pressure/expiratory positive airway pressure or positive end-expiratory pressure levels, as well as the time of orotracheal intubation were performed according to the criteria of the physician. All patients received aspiration of secretions, postural changes, incentive spirometry and bronchodilators.
Parameters analysed. After inclusion in the study, demographic data, the reason of mechanical ventilation, severity according to the Simplified Acute Physiology Score 3, organ failure according to the Sequential Organ Failure Assessment scale (both of them at intensive care unit admission) and comorbidities were recorded. The duration both of mechanical ventilation until the first extubation and time of spontaneous breathing trial were measured. Neurological variables (Glasgow Coma Score), haemodynamic variables [systolic blood pressure, diastolic blood pressure, mean blood pressure, heart rate], respiratory variables (respiratory rate, transcutaneous oxygen saturation) and blood gases (oxygen partial pressure, fraction of inspired oxygen, oxygen partial pressure to fraction of inspired oxygen ratio, carbon dioxide partial pressure, pH, bicarbonate and lactic acid) were recorded during the T-test of patients eligible to participate in the study and later, when they presented acute respiratory failure due to extubation failure. Similarly, ventilatory parameters were recorded during the 1st,2nd, and 8th hours of randomisation. Time from extubation to acute respiratory failure extubation failure was recorded. After extubation failure, the following variables were recorded: reintubation, tracheostomy, organ failure (cardiovascular, coagulation, renal, liver, neurological) using the Sequential Organ Failure Assessment scale and infectious complications (pneumonia or tracheobronchitis associated to mechanical ventilation, urinary tract infection, bacteraemia) were determined. Also the duration both of non-invasive ventilation. and oxygen therapy and globally of mechanical ventilation, were calculated. The mortality rates in the intensive care unit, in the hospital, and at 90 days were determined.
Sample size. Based on previous results, it was considered that the need for intubation could be reduced by 35%. The estimated sample size was 30 patients in each group [NIV group vs oxygen therapy] with a confidence interval [1-α] of 95% and power [1-β] of 80%. Comparative analyses were conducted using Student's t test or the Mann-Whitney test for the comparisons of quantitative variables for parametric and non-parametric characteristics, respectively. For qualitative variables, chi-square statistic or Fisher's exact test were used. Differences were considered significant if P <0.05. A per protocol analysis was performed. Multivariate analysis for repeated measures (with Bonferroni's correction) was performed with the aim of studying the influence either of NIV or oxygen therapy on respiratory parameters. The cumulative probability of survival was assessed using a Kaplan-Meier estimation of survival and a log-rank test to compare the two groups. The data were analysed using the statistical package SPSS 20.0.
- Conditions
- Respiratory Failure
- Being tested
- Non-invasive mechanical ventilation, Continuous positive airway pressure, Venturi mask, Reservoir mask
- Keywords
- Non-invasive mechanical ventilation, Oxygen therapy, Extubation failure
- Medical subject headings
- Respiratory Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-invasive mechanical ventilationDevice
Continuous positive airway pressureDevice
Venturi maskDevice
Reservoir maskDevice
| Study group | Role | What they receive |
|---|---|---|
| Non-invasive mechanical ventilation | Experimental | Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.
The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective. Receives: Device: Non-invasive mechanical ventilation; Device: Continuous positive airway pressure |
| Venturi mask | Active comparator | For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.
The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective. Receives: Device: Venturi mask; Device: Reservoir mask |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of Intubation
Need for intubation after assignment to non-invasive mechanical ventilation or oxygen therapy
Measured: from randomization to 1 week
Secondary outcomes (11)
Rate of Tracheotomy
Need for tracheotomy after reintubation, because of prolongation of mechanical ventilation
Measured: from randomization to 3 weeks
Intensive Care Unit Length of Stay
Duration of stay at intensive care unit
Measured: From intensive care unit admission to 2 months
Hospital Length of Stay
Duration of stay at hospital
Measured: From hospital admission to 3 months
Duration of Non-invasive Mechanical Ventilation or Oxygen Therapy
Duration of non-invasive mechanical ventilation or oxygen therapy after randomization until success or failure.
Measured: From randomization to one week
Duration of Global Mechanical Ventilation
Duration of mechanical ventilation until unsupported ventilation
Measured: From start of mechanical ventilation to one month
Rate of Intensive Care Unit Mortality
Mortality during intensive care unit stay
Measured: From intensive care unit admission to 2 months
Rate of Hospital Mortality
Mortality during hospital stay
Measured: From hospital admission to 3 months
Rate of 90 Days Mortality
Mortality at 90 days after randomization
Measured: 90 days after randomization
Rate of Ventilator Associated Pneumonia
Percentage of participants with lung infection during intensive care unit stay
Measured: From start of mechanical ventilation to 2 months
Rate of Urinary Tract Infection
Percentage of participants with urinary tract infection during intensive care unit stay
Measured: From intensive care unit admission to 2 months
Rate of Bacteremia
Percentage of participants with blood infection during intensive care unit stay
Measured: From intensive care unit admission to 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2019
- Study start29 Mar 2009
- Primary completion4 Jun 2016
- Study completion4 Sep 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- STUDY GROUP: Non-invasive ventilation using BiPAP Vision and continuous positive airway pressure (CPAP) systems CONTROL GROUP: Oxygen therapy
- Masking
- None (open label)
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alberto Belenguer, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- Investigators
- ALBERTO BELENGUER MUNCHARAZ, Principal investigator, HOSPITAL GENERAL UNIVERSITARIO CASTELLON
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03832387
- Sponsor's protocol ID
- HGCS03
- Status last verified
- May 2019
- First submitted
- 24 Jan 2019
- Last updated
- 4 Jun 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Belenguer-Muncharaz A, Mateu-Campos ML, Vidal-Tegedor B, Ferrandiz-Selles MD, Mico-Gomez ML, Altaba-Tena S, Arlandis-Tomas M, Alvaro-Sanchez R, Rodriguez-Martinez E, Rodriguez-Portillo J. Noninvasive ventilation versus conventional oxygen therapy after extubation failure in high-risk patients in an intensive care unit: a pragmatic clinical trial. Rev Bras Ter Intensiva. 2021 Oct 25;33(3):362-373. doi: 10.5935/0103-507X.20210059. eCollection 2021.
PubMed 35107547
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-Invasive Mechanical Ventilation Versus Oxygen Therapy in Patients With Acute Respiratory Failure After Extubation in a Intensive Care Unit
- ClinicalTrials.gov ID
- NCT03832387
- Acronym / sponsor ID
- HGCS03
- Conditions
- Respiratory Failure
- Keywords
- Non-invasive mechanical ventilation, Oxygen therapy, Extubation failure
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 77 participants (actual)
- Lead sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat ValencianaUniversity, hospital or other
- Study start
- 29 Mar 2009 (actual)
- Primary completion
- 4 Jun 2016 (actual)
- Study completion
- 4 Sep 2016 (actual)
- First posted
- 6 Feb 2019 (actual)
- Results
- Posted 28 May 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Non-invasive mechanical ventilation (NIV) has not exhibited a reduction of reintubation after extubation failure compared to oxygen therapy. The reduction of reintubation with NIV versus oxygen therapy in patients with extubation failure was evaluated.
A clinical trial was conducted that included patients who underwent mechanical ventilation and developed acute respiratory failure after extubation. After extubation failure, thirty-three were assigned to NIV and thirty-two were assigned to oxygen therapy.
Detailed description
Patients. Medical and surgical patients admitted to intensive care unit with 18 years of age or older in weaning from their first episode of mechanical ventilation for more than 24 hours were included. Patients with structural neurological disorder, acute toxic-metabolic neurological encephalopathy with neurological deficit [estimated by a Glasgow Coma Score <14 points] at the time of weaning, neuromuscular disease, chronic obstructive pulmonary disease receiving non-invasive ventilation, limitation of life support therapy during their admission, tracheostomized patients, spinal cord injuries, scheduled surgical procedure during the 48 hours following extubation, intensive care unit readmission, transfer to another centre or a contraindication to non-invasive ventilation were excluded.
Weaning protocol. The beginning of weaning was considered when patients were conscious, without pain, connected to mechanical ventilation in pressure support ventilation mode, fraction of inspired oxygen ≤0.5, positive end-expiratory pressure +5cmH20, dopamine ≤5 mcgr/kg/min or noradrenaline ≤0.2 mcgr/kg/min, temperature <38ºC and absence of metabolic acidosis. Weaning consisted of a spontaneous breathing trial, which is routinely performed in our unit with a T-tube connected to an oxygen source . The following conditions indicated a successful spontaneous breathing trial: oxygen partial pressure ≥60 mmHg or transcutaneous oxygen saturation>90% with fraction of inspired oxygen <0.5, carbon dioxide partial pressure <50 mmHg (or an increase <8 mmHg), pH >7.32, respiratory rate <35 bpm (or an increase <50%), heart rate <140 bpm (or an increase <20%), systolic blood pressure <180 mmHg, and absence of cardiac arrhythmias after a minimum period of 30-120 min. Once the test was completed, extubation and subsequent placement of a Venturi oxygen mask with 0.3-0.4 fraction of inspired oxygen was performed. The physician in charge was responsible for the process of removal of mechanical ventilation and subsequent extubation. In the case of T-tube test failure, the patient was reconnected to the ventilator. Patient who presented clinical deterioration within 48 hours after extubation (work of breathing, use of accessory muscles, paradoxical breathing) and/or respiratory-gasometric deterioration [respiratory rate >25 bpm or increase of >50% with respect to the baseline respiratory rate, oxygen partial pressure <65 mmHg, carbon dioxide partial pressure >45 mmHg or pH <7.33) [19] and who were candidates for non-invasive ventilation were included in the study. Extubation failure was classified as follows: 1) Acute respiratory failure secondary to airway problems: obstruction of the upper airway and aspiration or excess of secretions; 2) Acute respiratory failure not dependent of the airway: acute pulmonary oedema, congestive heart failure, hypoxemic and/or hypercapnic acute respiratory failure, encephalopathy and others (digestive bleeding, shock, etc.). Patients who required immediate reintubation after extubation failure were not included.
After confirming extubation failure and the possibility of eligibility to participate in the study, the patient was assigned to a group (non-invasive ventilation group or oxygen group) through the opening of a sealed envelope. Previously, a simple randomisation by a computerised system had been performed by a physician not involved in the study.
Non-invasive ventilation. BiPAP Vision and continuous positive airway pressure devices were used. For the BiPAP Vision, oronasal and facial masks and an active humidification system were used. Procedure: Once the patient was informed of the procedure, the type of mask was selected according to the clinical situation and anatomy of the patient, and the harness was placed. Ventilation was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. The rise time was 0.1-0.2 seconds. Continuous positive airway pressure. A continuous positive airway pressure device was used through the oronasal mask on the patient. The minimum initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O. The objective pressures of both devices were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. The fraction of inspired oxygen was increased in both devices until a transcutaneous oxygen saturation of 94-96% was achieved. Once the patient's cooperation and sufficient adaptability were achieved, the mask was adjusted to the harness with adjustable straps.
Oxygen therapy. The control group received oxygen therapy using a Venturi mask with an fraction of inspired oxygen up to 0.5 or using a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2 (estimated fraction of inspired oxygen of 1.0).
Both non-invasive ventilation/continuous positive airway pressure and oxygen therapy were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective. Withdrawal of non-invasive ventilation/continuous positive airway pressure was performed progressively with reduction of inspiratory airway pressure/expiratory positive airway pressure or positive end-expiratory pressure levels until complete disconnection of non-invasive ventilation. In both groups (study and control), after improvement, the fraction of inspired oxygen of the Venturi mask was set to 0.3-0.4. The criteria for failure of both non-invasive ventilation and oxygen therapy were: absence of clinical improvement (respiratory rate>35 bpm, use of accessory muscles, thoracoabdominal asynchrony, encephalopathy) or deterioration of oxygenation (decrease in oxygen partial pressure or in oxygen partial pressure to fraction of inspired oxygen ratio), haemodynamic (noradrenaline >0.5 mcgr/kg/min) or ventilation (increase in carbon dioxide partial pressure and decrease in pH) parameters. Modifications of fraction of inspired oxygen and inspiratory positive airway pressure/expiratory positive airway pressure or positive end-expiratory pressure levels, as well as the time of orotracheal intubation were performed according to the criteria of the physician. All patients received aspiration of secretions, postural changes, incentive spirometry and bronchodilators.
Parameters analysed. After inclusion in the study, demographic data, the reason of mechanical ventilation, severity according to the Simplified Acute Physiology Score 3, organ failure according to the Sequential Organ Failure Assessment scale (both of them at intensive care unit admission) and comorbidities were recorded. The duration both of mechanical ventilation until the first extubation and time of spontaneous breathing trial were measured. Neurological variables (Glasgow Coma Score), haemodynamic variables [systolic blood pressure, diastolic blood pressure, mean blood pressure, heart rate], respiratory variables (respiratory rate, transcutaneous oxygen saturation) and blood gases (oxygen partial pressure, fraction of inspired oxygen, oxygen partial pressure to fraction of inspired oxygen ratio, carbon dioxide partial pressure, pH, bicarbonate and lactic acid) were recorded during the T-test of patients eligible to participate in the study and later, when they presented acute respiratory failure due to extubation failure. Similarly, ventilatory parameters were recorded during the 1st,2nd, and 8th hours of randomisation. Time from extubation to acute respiratory failure extubation failure was recorded. After extubation failure, the following variables were recorded: reintubation, tracheostomy, organ failure (cardiovascular, coagulation, renal, liver, neurological) using the Sequential Organ Failure Assessment scale and infectious complications (pneumonia or tracheobronchitis associated to mechanical ventilation, urinary tract infection, bacteraemia) were determined. Also the duration both of non-invasive ventilation. and oxygen therapy and globally of mechanical ventilation, were calculated. The mortality rates in the intensive care unit, in the hospital, and at 90 days were determined.
Sample size. Based on previous results, it was considered that the need for intubation could be reduced by 35%. The estimated sample size was 30 patients in each group [NIV group vs oxygen therapy] with a confidence interval [1-α] of 95% and power [1-β] of 80%. Comparative analyses were conducted using Student's t test or the Mann-Whitney test for the comparisons of quantitative variables for parametric and non-parametric characteristics, respectively. For qualitative variables, chi-square statistic or Fisher's exact test were used. Differences were considered significant if P <0.05. A per protocol analysis was performed. Multivariate analysis for repeated measures (with Bonferroni's correction) was performed with the aim of studying the influence either of NIV or oxygen therapy on respiratory parameters. The cumulative probability of survival was assessed using a Kaplan-Meier estimation of survival and a log-rank test to compare the two groups. The data were analysed using the statistical package SPSS 20.0.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- STUDY GROUP: Non-invasive ventilation using BiPAP Vision and continuous positive airway pressure (CPAP) systems CONTROL GROUP: Oxygen therapy
| Arm | Type | Receives |
|---|---|---|
| Non-invasive mechanical ventilation | Experimental | Device: Non-invasive mechanical ventilation, Device: Continuous positive airway pressureNon-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O. The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective. |
| Venturi mask | Active comparator | Device: Venturi mask, Device: Reservoir maskFor oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2. The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Medical and surgical ICU patients with 18 years of age or older
- First episode of mechanical ventilation for more than 24 hours
Key exclusion criteria (11 listed)
- Structural neurological disorder
- Acute toxic-metabolic neurological encephalopathy with neurological deficit [estimated by a Glasgow Coma Score (GCS) <14 points] at the time of weaning
- Neuromuscular disease
- Chronic obstructive pulmonary disease (COPD) receiving NIV
- Limitation of life support therapy during their admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-invasive mechanical ventilation | Device | Non-invasive mechanical ventilation |
| Continuous positive airway pressure | Device | Non-invasive mechanical ventilation |
| Venturi mask | Device | Venturi mask |
| Reservoir mask | Device | Venturi mask |
Primary outcome
Rate of Intubation
Time frame: from randomization to 1 week
Need for intubation after assignment to non-invasive mechanical ventilation or oxygen therapy
11 secondary outcomes
Rate of Tracheotomy
Time frame: from randomization to 3 weeks
Intensive Care Unit Length of Stay
Time frame: From intensive care unit admission to 2 months
Hospital Length of Stay
Time frame: From hospital admission to 3 months
Duration of Non-invasive Mechanical Ventilation or Oxygen Therapy
Time frame: From randomization to one week
Duration of Global Mechanical Ventilation
Time frame: From start of mechanical ventilation to one month
Rate of Intensive Care Unit Mortality
Time frame: From intensive care unit admission to 2 months
Rate of Hospital Mortality
Time frame: From hospital admission to 3 months
Rate of 90 Days Mortality
Time frame: 90 days after randomization
Rate of Ventilator Associated Pneumonia
Time frame: From start of mechanical ventilation to 2 months
Rate of Urinary Tract Infection
Time frame: From intensive care unit admission to 2 months
Rate of Bacteremia
Time frame: From intensive care unit admission to 2 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 35107547Belenguer-Muncharaz A, Mateu-Campos ML, Vidal-Tegedor B, Ferrandiz-Selles MD, Mico-Gomez ML, Altaba-Tena S, Arlandis-Tomas M, Alvaro-Sanchez R, Rodriguez-Martinez E, Rodriguez-Portillo J. Noninvasive ventilation versus conventional oxygen therapy after extubation failure in high-risk patients in an intensive care unit: a pragmatic clinical trial. Rev Bras Ter Intensiva. 2021 Oct 25;33(3):362-373. doi: 10.5935/0103-507X.20210059. eCollection 2021.
- Individual participant dataSharing planned: No
Related trials for Respiratory Failure
Recruiting
Measuring Nasal Airway Changes After VivAer Treatment Using AI Analysis
Nasal Airway Obstruction
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Recruiting
Vasopressor Agents in Pulmonary Hypertension Crisis
Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
RecruitingPhase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Viral Lung Infection and Acute Respiratory Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ALBERTO BELENGUER MUNCHARAZ principal investigator
HOSPITAL GENERAL UNIVERSITARIO CASTELLON
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Non-invasive mechanical ventilation, Continuous positive airway pressure and Venturi mask in people with Respiratory Failure, run by Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 May 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of Intubation (time frame: from randomization to 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03832387, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2019.